SG10201601301RA - Methods for predicting and improving the survival of gastric cancer patients - Google Patents
Methods for predicting and improving the survival of gastric cancer patientsInfo
- Publication number
- SG10201601301RA SG10201601301RA SG10201601301RA SG10201601301RA SG10201601301RA SG 10201601301R A SG10201601301R A SG 10201601301RA SG 10201601301R A SG10201601301R A SG 10201601301RA SG 10201601301R A SG10201601301R A SG 10201601301RA SG 10201601301R A SG10201601301R A SG 10201601301RA
- Authority
- SG
- Singapore
- Prior art keywords
- predicting
- survival
- improving
- methods
- cancer patients
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161471678P | 2011-04-04 | 2011-04-04 | |
US201261590787P | 2012-01-25 | 2012-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201601301RA true SG10201601301RA (en) | 2016-03-30 |
Family
ID=46000356
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013071998A SG193626A1 (en) | 2011-04-04 | 2012-04-04 | Methods for predicting and improving the survival of gastric cancer patients |
SG10201601301RA SG10201601301RA (en) | 2011-04-04 | 2012-04-04 | Methods for predicting and improving the survival of gastric cancer patients |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013071998A SG193626A1 (en) | 2011-04-04 | 2012-04-04 | Methods for predicting and improving the survival of gastric cancer patients |
Country Status (15)
Country | Link |
---|---|
US (2) | US20140099300A1 (es) |
EP (1) | EP2694972B8 (es) |
JP (1) | JP2014517259A (es) |
KR (1) | KR20140020318A (es) |
CN (1) | CN103597354B (es) |
AU (1) | AU2012240242A1 (es) |
CA (1) | CA2831468A1 (es) |
DK (1) | DK2694972T3 (es) |
ES (1) | ES2639650T3 (es) |
IL (1) | IL228579A0 (es) |
MX (1) | MX339340B (es) |
NZ (1) | NZ615738A (es) |
RU (1) | RU2013148768A (es) |
SG (2) | SG193626A1 (es) |
WO (1) | WO2012138785A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101327533B1 (ko) * | 2012-12-11 | 2013-11-08 | 사회복지법인 삼성생명공익재단 | 환자 맞춤형 항암제 선별용 시스템 |
KR20160024639A (ko) | 2014-08-26 | 2016-03-07 | 삼성전자주식회사 | c-Met 표적 치료제의 저항성 또는 효능 예측을 위한 바이오마커 PDGF |
CN105588943B (zh) * | 2016-01-28 | 2018-03-02 | 山东省肿瘤防治研究院 | 一种胃癌患者外周血循环肿瘤细胞Her‑2基因的检测方法 |
CN105986034A (zh) * | 2016-06-15 | 2016-10-05 | 南京卡迪睿伯生物技术有限公司 | 一组胃癌基因的应用 |
TWI639430B (zh) * | 2016-08-27 | 2018-11-01 | 中國醫藥大學 | 醫藥組合物用於製備治療胃癌藥物的用途 |
WO2020092860A1 (en) * | 2018-11-01 | 2020-05-07 | The Jackson Laboratory | Gastric cancer treatments |
JP7493237B2 (ja) * | 2018-11-14 | 2024-05-31 | 学校法人金沢医科大学 | びまん性胃がんを治療するための医薬組成物 |
KR20220078117A (ko) | 2020-12-03 | 2022-06-10 | 원광대학교산학협력단 | 혈액샘플을 이용한 코로나 환자 사망률 예측 시스템 및 방법 |
CN114594252A (zh) * | 2020-12-03 | 2022-06-07 | 复旦大学附属中山医院 | 循环肿瘤细胞形态学特征在胃癌临床诊疗中的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5532138A (en) | 1990-04-26 | 1996-07-02 | Behringwerke Ag | Method and kits for determining peroxidatively active catalysts |
US5332662A (en) | 1992-07-31 | 1994-07-26 | Syntex (U.S.A.) Inc. | Methods for determining peroxidatively active substances |
DE69417242T2 (de) | 1993-09-03 | 1999-07-08 | Behringwerke Ag | Fluoreszenz-sauerstoffkanalisation-immunteste |
JP5154557B2 (ja) | 2006-09-21 | 2013-02-27 | ネステク ソシエテ アノニム | 希少循環細胞における多様なシグナル伝達物質検出のための抗体に基づくアレイ |
BRPI0717416A2 (pt) * | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
ES2526211T3 (es) | 2007-07-13 | 2015-01-08 | Nestec S.A. | Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos |
CN102016581B (zh) | 2008-02-25 | 2014-07-30 | 雀巢产品技术援助有限公司 | 用抗体阵列选择乳腺癌治疗药物 |
CN102361883A (zh) * | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-1/抗-c-Met抗体 |
WO2010132723A1 (en) | 2009-05-14 | 2010-11-18 | Prometheus Laboratories Inc. | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
JP5795311B2 (ja) * | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
KR20120110168A (ko) | 2009-10-20 | 2012-10-09 | 프로메테우스 레버러터리스 인코포레이티드 | 종양원성 융합 단백질을 검출하기 위한 근접-매개 검정법 |
JPWO2011125458A1 (ja) * | 2010-04-02 | 2013-07-08 | 富士レビオ株式会社 | 抗癌剤の効果の診断用マーカー |
-
2012
- 2012-04-04 MX MX2013011431A patent/MX339340B/es active IP Right Grant
- 2012-04-04 SG SG2013071998A patent/SG193626A1/en unknown
- 2012-04-04 NZ NZ615738A patent/NZ615738A/en not_active IP Right Cessation
- 2012-04-04 ES ES12716858.1T patent/ES2639650T3/es active Active
- 2012-04-04 CA CA2831468A patent/CA2831468A1/en not_active Abandoned
- 2012-04-04 RU RU2013148768/15A patent/RU2013148768A/ru not_active Application Discontinuation
- 2012-04-04 EP EP12716858.1A patent/EP2694972B8/en active Active
- 2012-04-04 KR KR1020137029113A patent/KR20140020318A/ko not_active Application Discontinuation
- 2012-04-04 SG SG10201601301RA patent/SG10201601301RA/en unknown
- 2012-04-04 JP JP2014503964A patent/JP2014517259A/ja active Pending
- 2012-04-04 AU AU2012240242A patent/AU2012240242A1/en not_active Abandoned
- 2012-04-04 WO PCT/US2012/032206 patent/WO2012138785A1/en active Application Filing
- 2012-04-04 DK DK12716858.1T patent/DK2694972T3/en active
- 2012-04-04 CN CN201280027365.2A patent/CN103597354B/zh not_active Expired - Fee Related
-
2013
- 2013-09-29 IL IL228579A patent/IL228579A0/en unknown
- 2013-10-02 US US14/044,792 patent/US20140099300A1/en not_active Abandoned
-
2017
- 2017-06-14 US US15/623,011 patent/US20170285044A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2013148768A (ru) | 2015-05-10 |
CN103597354B (zh) | 2016-04-20 |
AU2012240242A1 (en) | 2013-10-10 |
SG193626A1 (en) | 2013-10-30 |
JP2014517259A (ja) | 2014-07-17 |
ES2639650T3 (es) | 2017-10-27 |
WO2012138785A1 (en) | 2012-10-11 |
EP2694972B8 (en) | 2017-08-16 |
US20140099300A1 (en) | 2014-04-10 |
NZ615738A (en) | 2015-11-27 |
IL228579A0 (en) | 2013-12-31 |
CA2831468A1 (en) | 2012-10-11 |
MX339340B (es) | 2016-05-20 |
KR20140020318A (ko) | 2014-02-18 |
CN103597354A (zh) | 2014-02-19 |
DK2694972T3 (en) | 2017-10-02 |
EP2694972A1 (en) | 2014-02-12 |
US20170285044A1 (en) | 2017-10-05 |
MX2013011431A (es) | 2014-06-06 |
EP2694972B1 (en) | 2017-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1254859A1 (zh) | 治療乳腺癌的方法 | |
HK1199099A1 (en) | Methods and compositions for the treatment and diagnosis of cancer | |
HK1199100A1 (en) | Methods and compositions for the treatment and diagnosis of colorectal cancer | |
SI2619576T1 (sl) | Sredstva in metode za predvidevanje odziva rakavega pacienta na zdravljenje | |
IL228738A0 (en) | Antibodies for cancer treatment | |
ZA201308111B (en) | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor | |
HK1203091A1 (en) | Methods for diagnosis of lung cancer | |
IL228579A0 (en) | Methods for predicting and improving the survival of gastric cancer patients | |
GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
EP2688594A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
EP2723924A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER | |
SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
EP2651443A4 (en) | ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND THE MIGRATION OF CANCER CELLS | |
EP2700652A4 (en) | DIAGNOSIS AND TREATMENT OF CANCER BY ANTI-ITM2A ANTIBODIES | |
HK1185874A1 (zh) | 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺 | |
IL228430A0 (en) | Cancer treatment | |
SG11201402115TA (en) | Methods for diagnosis and/or prognosis of gynecological cancer | |
IL275636A (en) | Medical combination for cancer treatment | |
EP2635121A4 (en) | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | |
EP2750508A4 (en) | COMPOUNDS AND THERAPEUTIC METHODS | |
EP2710379A4 (en) | METHODS OF DETERMINING THE PROBABILITY OF SURVIVAL AND EVALUATION OF THE PROBABILITY OF METASTASES IN CANCER PATIENTS | |
PL2746404T3 (pl) | Środek przeciwnowotworowy i sposób przewidywania efektu terapeutycznego u pacjentów z rakiem jelita grubego z mutacją kras | |
EP2849786A4 (en) | METHOD FOR THE TREATMENT OF GASCULAR CANCER | |
EP2709730A4 (en) | TREATMENT AND PROGNOSIS OF CANCER | |
HK1213584A1 (zh) | 用於治療癌症的 抗體及方法 |